Kadmon Pharms Llc Drug Patent Portfolio

Kadmon Pharms Llc owns 1 orange book drug protected by 5 US patents Given below is the list of Kadmon Pharms Llc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11311541 Treatment of GVHD 09 Apr, 2035
Active
US10183931 Rho kinase inhibitors 07 Oct, 2033
Active
US10696660 Rho kinase inhibitors 07 Oct, 2033
Active
US9815820 Rho kinase inhibitors 07 Oct, 2033
Active
US8357693 Pharmacokinetically improved compounds 30 Oct, 2029
Active


Given below is the list of recent legal activities going on the following drug patents of Kadmon Pharms Llc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 10 Jul, 2024 US8357693
transaction for FDA Determination of Regulatory Review Period 18 Jan, 2024 US8357693
Payment of Maintenance Fee, 4th Year, Large Entity 13 Dec, 2023 US10696660
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US8357693
Electronic Review 01 Jun, 2023 US10696660
Mail Certificate of Correction Memo 31 May, 2023 US10696660
Post Issue Communication - Certificate of Correction 30 May, 2023 US10696660
Certificate of Correction Memo 26 May, 2023 US10696660
Electronic Review 25 May, 2023 US10183931
Electronic Review 25 May, 2023 US9815820
Mail Certificate of Correction Memo 24 May, 2023 US9815820
Mail Certificate of Correction Memo 24 May, 2023 US10183931
Certificate of Correction Memo 23 May, 2023 US10183931
Post Issue Communication - Certificate of Correction 23 May, 2023 US9815820
Post Issue Communication - Certificate of Correction 23 May, 2023 US10183931


Kadmon Pharms Llc Drug Patents' Oppositions Filed in EPO

Kadmon Pharms Llc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 28, 2023, by Elkington And Fife Llp. This opposition was filed on patent number EP13843426A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP13843426A Feb, 2023 SANDOZ AG Granted and Under Opposition
EP13843426A Feb, 2023 ELKINGTON AND FIFE LLP Granted and Under Opposition


Kadmon Pharms Llc's Family Patents

Kadmon Pharms Llc drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 36.5% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Kadmon Pharms Llc Drug List

Given below is the complete list of Kadmon Pharms Llc's drugs and the patents protecting them.


1. Rezurock

Rezurock is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11311541 Treatment of GVHD 09 Apr, 2035
(10 years from now)
Active
US10183931 Rho kinase inhibitors 07 Oct, 2033
(9 years from now)
Active
US10696660 Rho kinase inhibitors 07 Oct, 2033
(9 years from now)
Active
US9815820 Rho kinase inhibitors 07 Oct, 2033
(9 years from now)
Active
US8357693 Pharmacokinetically improved compounds 30 Oct, 2029
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rezurock's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List